New treatments for trichomoniasis using proteasome inhibitors
Proteasome inhibitors against mucosal protozoan pathogens
This study is looking at a new way to treat trichomoniasis, a common infection that can be tough to get rid of, especially in women with stubborn cases, by using special drugs that target a part of the parasite that helps it survive, aiming to find a more effective treatment with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10903829 on NIH RePORTER |
What this research studies
This research investigates the use of proteasome inhibitors to treat trichomoniasis, a common sexually transmitted infection caused by Trichomonas vaginalis. The study aims to develop new antimicrobial therapies that are effective against drug-resistant strains of the parasite, particularly in women who may experience prolonged infections. By targeting the proteasome, a crucial component for the parasite's survival, the research seeks to provide a more effective treatment option with fewer side effects compared to existing medications. The approach includes biochemical characterization of the proteasome from the parasite and testing the efficacy of these inhibitors in laboratory models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with trichomoniasis, particularly women experiencing persistent infections.
Not a fit: Patients who do not have trichomoniasis or those who are not affected by sexually transmitted infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for trichomoniasis, reducing the risk of associated health complications.
How similar studies have performed: Previous studies have shown promise in using proteasome inhibitors for similar applications, indicating potential for success in this novel approach.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Eckmann, Lars — University of California, San Diego
- Study coordinator: Eckmann, Lars
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.